Drug intelligence / Profile preview

86Y-Pep-1L

Development stage
Preclinical
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

86Y-Pep-1L is a radiopharmaceutical diagnostic tracer consisting of the IL-13RA2-specific peptide Pep-1L conjugated to a chelator and labeled with the positron-emitting isotope Yttrium-86 (86Y). It is designed for selective PET/CT imaging of tumors overexpressing the interleukin-13 receptor alpha 2 (IL-13RA2), such as pancreatic ductal adenocarcinoma and metastatic melanoma. Unlike the ubiquitous IL-13RA1, IL-13RA2 is a tumor-restricted biomarker, making it an ideal target for diagnostic and theranostic applications. Preclinical studies demonstrate fast clearance via glomerular filtration and high tumor-to-muscle uptake ratios, supporting its potential for non-invasive visualization of IL-13RA2-positive malignancies.

Other names
Yttrium-86-labeled Pep-1LYttrium86-labeled Pep-1LYttrium 86-labeled Pep-1L
02

Targets

IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on 86Y-Pep-1L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 86Y-Pep-1L.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call